A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16967580.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a randomized, double-blind, crossover study, we evaluated the effect of intravenous lidocaine (5 mg/kg body weight over 30 min) on the neuropathic pain of advanced cancer patients. Pain intensity, assessed by a visual analogue scale, did not show any significant difference between lidocaine and placebo infusion. The blinded choice of patients and investigators also suggested no significant improvement from lidocaine when given by this regimen. Intravenous lidocaine does not appear to have a significant analgesic effect on neuropathic cancer pain.
Medical subject headings
- Lidocaine
- Neoplasms
- Neuralgia
- Pain Measurement
- Palliative Care
- Terminal Care